Dyadic International, Inc. (OTCQX: DYAI)  is a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and cost to patients and the healthcare system - but most importantly to save lives.

Biotechnology

Dyadic International

Mark A. Emalfarb

Joseph Hazelton

Joe Hazelton

Ping W. Rawson

The Leadership Team at Dyadic International is responsible for driving the company's strategic vision and operational effectiveness. They oversee the integration of innovative biotechnology solutions, including the C1 expression system, to expedite the development and commercialization of biologic vaccines and drugs. This team collaborates across functions to ensure financial stability, foster research and business development, and ultimately enhance patient access to life-saving therapies.

Leadership Team

About

Team members

Other teams at Dyadic International

Business Development and Licensing

Finance and Accounting